Abstract
Antipsychotics are a group of drugs used to treat schizophrenia, some of which are also used to treat mood disorders and anxiety disorders. Antipsychotic drugs are sometimes referred to as neuroleptic drugs due to the neuroleptic effect of early antipsychotics. These drugs are roughly classified into first-generation antipsychotics (FGA) based on their dopamine D2 receptor-blocking action and second-generation antipsychotics (SGA) represented by a serotonin-dopamine antagonist (SDA). There is no significant difference in the therapeutic effect among antipsychotics, but side effects differ between drugs. The development of antipsychotics began with the serendipitous discovery of chlorpromazine in the 1950s and was dominated by phenothiazines and butyrophenones, which act as dopamine D2 receptor blockers, based on the dopamine hypothesis of the pathogenesis of schizophrenia. However, because FGA present challenges such as drug-induced extrapyramidal symptoms, hyperprolactinemia, and worsening negative symptoms, SGA focusing on actions other than D2 receptors have become the mainstay of treatment since the 1990s. In this chapter, the pharmacological action and biochemical function of antipsychotic drugs are explained.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332(7539):455–9.
Araki T, Yamasue H, Sumiyoshi T, Kuwabara H, Suga M, Iwanami A, Kato N, Kasai K. Perospirone in the treatment of schizophrenia: effect on verbal memory organization. Prog Neuro-Psychopharmacol Biol Psychiatry. 2006;30(2):204–8.
Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(6):724–63.
Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007;30(5):194–202.
Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, Moore NA. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry. 1997;58(Suppl 10):28–36.
Corena-McLeod M. Comparative pharmacology of risperidone and paliperidone. Drugs R D. 2015;15(2):163–74.
Creese I, Burt DR, Snyder SH. Dopamine receptors and average clinical doses. Science. 1976;194(4264):546.
Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148(11):1474–86.
Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs. 2010;24(1):65–84.
Granger B, Albu S. The haloperidol story. Ann Clin Psychiatry. 2005;17(3):137–40.
Gross G, Wicke K, Drescher KU. Dopamine D3 receptor antagonism--still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedeberg’s Arch Pharmacol. 2013;386(2):155–66.
Hamamura T, Harada T. Unique pharmacological profile of aripiprazole as the phasic component buster. Psychopharmacology (Berl). 2007;191(3):741–3.
Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology. 2008;33(10):2303–12.
Joyce EM, Roiser JP. Cognitive heterogeneity in schizophrenia. Curr Opin Psychiatry. 2007;20(3):268–72.
Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153(4):466–76.
Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry. 2001;158(3):360–9.
Keks N, Hope J, Schwartz D, McLennan H, Copolov D, Meadows G. Comparative tolerability of dopamine D2/3 receptor partial agonists for schizophrenia. CNS Drugs. 2020;34(5):473–507.
Kornhuber J, Riederer P, Reynolds GP, Beckmann H, Jellinger K, Gabriel E. 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm. 1989;75(1):1–10.
Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519–26.
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.
Lieberman JA, Mailman R, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry. 1998;44(11):1099–117.
Mauri MC, Bravin S, Bitetto A, Rudelli R, Invernizzi G. A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Drug Saf. 1996;14(5):288–98.
Meftah AM, Deckler E, Citrome L, Kantrowitz JT. New discoveries for an old drug: a review of recent olanzapine research. Postgrad Med. 2020;132(1):80–90.
Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses. 2012;6(3):134–44.
Michael JO, Akira S, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86–97.
Nicola SM, Surmeier J, Malenka RC. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci. 2000;23(2):185–215.
Nucifora FC Jr, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017;14(3):750–61.
Ohlow MJ, Moosmann B. Phenothiazine: the seven lives of pharmacology’s first lead structure. Drug Discov Today. 2011;16(3–4):119–31.
Pytliak M, Vargová V, MechÃrová V, Felšöci M. Serotonin receptors – from molecular biology to clinical applications. Physiol Res. 2011;60(1):15–25.
Remington G. Alterations of dopamine and serotonin transmission in schizophrenia. Prog Brain Res. 2008;172:117–40.
Reyad AA, Mishriky R. Asenapine: pharmacological aspects and role in psychiatric disorders. Psychiatr Danub. 2019;31(2):157–61.
Robert AM, Anissa AD, Oliver DH. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci. 2019;42(3):205–20.
Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998;3(2):123–34.
Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976;261(5562):717–9.
Seeman P, Ulpian C, Bergeron C, Riederer P, Jellinger K, Gabriel E, Reynolds GP, Tourtellotte WW. Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science. 1984;225(4663):728–31.
Stahl SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. 2016;21(1):1–6.
van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther. 1966;160(2):492–4.
Waugh DJ, Gaivin RJ, Damron DS, Murray PA, Perez DM. Binding, partial agonism, and potentiation of alpha(1)-adrenergic receptor function by benzodiazepines: a potential site of allosteric modulation. J Pharmacol Exp Ther. 1999;291(3):1164–71.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Yonezawa, K., Kanegae, S., Ozawa, H. (2022). Antipsychotics/Neuroleptics: Pharmacology and Biochemistry. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-62059-2_52
Download citation
DOI: https://doi.org/10.1007/978-3-030-62059-2_52
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-62058-5
Online ISBN: 978-3-030-62059-2
eBook Packages: MedicineReference Module Medicine